Management ChangeJun 18, 2026, 05:16 PM
Petros Pharmaceuticals Appoints Robert Weinstein as New CAO
AI Summary
Petros Pharmaceuticals announced the mutual separation of Mitchell Arnold from his roles as Vice President of Finance, Principal Accounting Officer, and Principal Financial Officer, effective June 18, 2026. In connection with his departure, Mr. Arnold will receive a severance package including a $38,500 payment, acceleration of 3,000 unvested shares, and up to two months of COBRA premium coverage. Concurrently, the company appointed Robert Weinstein to succeed Mr. Arnold in these positions, effective immediately. Mr. Weinstein brings over thirty years of extensive accounting and finance experience to Petros Pharmaceuticals.
Key Highlights
- Mitchell Arnold separated from his roles as VP of Finance, Principal Accounting Officer, and Principal Financial Officer, effective June 18, 2026.
- Arnold will receive a severance payment of $38,500, representing two months of base salary.
- 3,000 unvested shares from his Restricted Stock Award Agreement will be accelerated.
- Arnold will receive a $100 lump-sum cash payment for estimated taxes on equity awards.
- The company will pay COBRA premiums for up to two months for Arnold's health, dental, and vision benefits.
- Robert Weinstein was appointed Chief Accounting Officer, Principal Financial Officer, and Principal Accounting Officer, effective June 18, 2026.
- Weinstein has over thirty years of accounting and finance experience, including CFO roles at publicly-traded biotechnology and energy companies.
- Weinstein previously served as CFO of TAO Synergies Inc. (formerly Synaptogenix, Inc.) since October 2013.
Price Impact
More from PTPI